Insulin Injections Get Their First Autonomous AI Dose Adjuster as FDA Clears DreaMed's MODI App

The FDA has cleared the first prescription software that autonomously adjusts insulin doses for type 2 diabetes patients using daily injections, marking a significant expansion of algorithmic dose optimization beyond the small pump-user population. DreaMed Diabetes Ltd.'s MODI application received 510(k) clearance as software-as-a-medical-device (SaMD) that continuously translates streaming continuous glucose monitor (CGM) data and patient-logged injection information into specific dose recommendations delivered directly to patients via mobile interface.

Closing the Gap for the Injection Majority

The clearance addresses a longstanding disparity in diabetes technology: while insulin pump users have benefited from automated dose adjustments, the 85% of insulin-dependent patients who rely on subcutaneous injections have been left with manual titration workflows that require physician review and approval. MODI eliminates this bottleneck by operating autonomously between office visits, without requiring clinicians to configure upfront dosing parameters or manually approve each adjustment.

The application is indicated for adults aged 18 and older with type 2 diabetes using long-acting basal insulin, either alone or combined with rapid-acting prandial insulin in multiple daily injection (MDI) regimens. According to the source, the algorithm dynamically adjusts therapy based on real-time CGM streams, fundamentally changing the care delivery model for injectable insulin management.

From Academic Spinout to Commercial Clearance

DreaMed Diabetes spun out in 2014 from Schneider Children's Medical Center, part of Israel's Clalit Health Services network. The company has raised $35.5 million in total capital, including $12.5 million in equity from investors such as Medtronic, eHealth Ventures, SIBF, and OurCrowd, plus $23 million in non-dilutive research grants.

The MODI product name carries personal significance: it honors Modi (Mordechai) Amir, who was killed on October 7, and was developed through the Next October initiative with his family's blessing, according to the source.

Medtronic's position as both investor and potential competitor in the CGM-integrated decision support space adds strategic complexity to the clearance. The company must now evaluate whether its own platforms can match MODI's level of autonomy for non-pump users in what represents a substantially larger addressable market than the pump-dependent population.

Implications for Diabetes Care Delivery

For healthcare providers, MODI promises to relieve the administrative burden of manual insulin titration that strains primary care and endocrinology practices. The autonomous operation model enables continuous optimization without the workflow bottleneck of reviewing each adjustment between scheduled appointments.

Patients using injectable insulin gain access to algorithm-driven dose optimization previously limited to pump users, potentially improving glycemic control without additional clinic visits or waiting for provider callbacks to modify therapy. The platform's support for both basal-only and basal-bolus MDI regimens extends its applicability beyond earlier pilots that focused exclusively on once-daily basal insulin.

The regulatory precedent established by MODI's clearance may accelerate development of similar autonomous titration platforms, as competitors in the CGM-integrated decision support category assess whether fully autonomous, direct-to-patient algorithms will become the standard of care for the injection-based insulin market.

Sources

1. FDA Clears DreaMed MODI: First CGM-Driven Insulin Dose Optimization App for Type 2 Injection Therapy — HIT Consultant